MaaT Pharma announced today the results from its ODYSSEE (NCT02928523) Phase 1b/2a clinical trial demonstrating that the Company’s proprietary MaaT Microbiome Restoration Biotherapeutic (MMRB) therapeutic is able to restore a functional microbiome in acute myeloid […]
Together with colleagues from Sweden and Luxembourg, scientists from the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg have observed that, during a natural vaginal birth, specific bacteria from the mother’s gut […]
Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, announced the initiation of a Phase 1 clinical study in healthy volunteers of […]
Upon analyzing the accumulated evidence that microbes inhabit or visit the brain and likely trigger Alzheimer’s disease, Leslie Norins, MD, PhD, concluded, “The suspects have been reliably placed at the crime scene.” Dr. Norins is CEO […]
The successful introduction of the 2018 Pharmabiotics Young Investigator Awards set the stage for its development as one of the most important and prestigious awards for young microbiome researchers. Co-initiated by the Pharmabiotic Research Institute […]
Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that it has successfully completed an End-of-Phase 2 […]
Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on nucleic acid and protein stabilization and purification, as well as providing high quality services to the scientific community, today announced that it […]
This summary of the 6th R&D and Business Collaboration Forum was authored by Anusha Gandhi from Microbiome Insights. The original version can be found here on their blog Leaders in the microbiome industry met in San […]
Newly published research shows that a saliva-based biomarker panel and associated algorithm could improve the ability to accurately identify children with autism spectrum disorder (ASD) in its earliest stages, announced Quadrant Biosciences Inc. In a […]
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, announces the randomisation of the first patient in a Phase II clinical trial of Blautix in patients with Irritable Bowel Syndrome […]
Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, announced preclinical data for VE800, the Company’s orally-administered, live biotherapeutic product candidate in […]